The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 14, 2023

Filed:

Mar. 21, 2019
Applicant:

Vertical Bio Ag, Basel, CH;

Inventors:

Cristina Basilico, Pavarolo, IT;

Elisa Vigna, Villarbasse, IT;

Paolo Maria Comoglio, Arignano, IT;

Assignee:

Vertical Bio AG, Basel, CH;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 14/71 (2006.01); A61P 3/00 (2006.01); A61P 35/00 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61P 31/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 38/179 (2013.01); A61K 39/39558 (2013.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); C07K 14/71 (2013.01); A61K 2039/505 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01);
Abstract

An anti-HGFR antibody fragment in combination with an extracellular portion of human HGFR for use in the treatment of a patient suffering from a tumor and/or metastasis, wherein: (i) the anti-HGFR antibody fragment has only one paratope able to bind to an epitope of the extracellular portion of human HGFR and has antagonist activity towards HGFR, (ii) the extracellular portion of human HGFR is capable of binding to HGF in a stable manner and contains at least one amino acid mutation at the epitope recognized by the anti-HGFR antibody fragment to prevent binding of the anti-HGFR antibody fragment thereto, and (iii) the anti-HGFR antibody fragment and the extracellular portion of human HGFR are suitable for administration to the patient are suitable for administration to the patient (a) in a protein form or (b) in a nucleic acid form.


Find Patent Forward Citations

Loading…